Zevra Therapeutics, Inc. ZVRA
Updated: 9 Aug 2026
No signal published yet
We already track Zevra Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Zevra Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zevra Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 5, 2026, Zevra Therapeutics reported its second-quarter 2026 financial results, posting net revenue of $39.7 million, up 53% year-over-year. The top-line growth was primarily driven by $30.2 million in MIPLYFFA sales during the quarter. The company ended the period with $260.2 million in cash reserves while requesting a re-examination from the European Medicines Agency following a negative CHMP opinion in July 2026.
What Firelda Watch includes for Zevra Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Zevra Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zevra Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more